NCT00404521View on ClinicalTrials.gov

A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

PHASE1TerminatedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Solid Tumors

Interventions

DRUG

PM02734

Administered every 3 weeks, intravenously, over 30 minutes

Trial Locations (1)

60637

Cancer Research Center. University of Chicago Hospitals, Chicago

Sponsors

Lead Sponsor

All Listed Sponsors

lead

PharmaMar

INDUSTRY